LMTK3: A Protein Regulator of Synaptic Plasticity and Neural Circuit Development
LMTK3: A Protein Regulator of Synaptic Plasticity and Neural Circuit Development
LMTK3 (PPP1R101) is a protein that is expressed in various tissues of the body, including the brain. It is a key regulator of synaptic plasticity, which is the ability of the brain to change and adapt over time. LMTK3 has been shown to play a role in the development and maintenance of neural circuits, and is often used as a drug target or biomarker for various neurological and psychiatric disorders.
The PPP1R101 gene encodes a protein that is known as the protein kinase PPP1R101. This protein is highly conserved across various species, and is found in a wide range of organisms, including bacteria, yeast, plants, and animals. LMTK3 is a splicing variant of the PPP1R101 gene that has been shown to have unique functions in various cellular processes.
One of the key functions of LMTK3 is its role in synaptic plasticity. Synaptic plasticity is the ability of the brain to change and adapt over time, and is a critical factor in the development and maintenance of neural circuits. LMTK3 has been shown to play a key role in this process by regulating the activity of other genes that are involved in synaptic plasticity.
For example, LMTK3 has been shown to regulate the activity of the neurotransmitter receptor N-methyl-D-aspartate (NMDA). NMDA is involved in a variety of cellular processes, including synaptic plasticity, and is known to play a role in the regulation of pain, anxiety, and other neurological disorders. LMTK3 has been shown to regulate the activity of NMDA receptors by phosphorylation and inhibition, which can lead to changes in the levels of NMDA in the brain.
Another function of LMTK3 is its role in the regulation of neurotransmitter release. Neurotransmitters are chemical messengers that are used by the brain to communicate with other cells and tissues. LMTK3 has been shown to play a key role in the regulation of neurotransmitter release by interacting with the neurotransmitter receptor, which is a protein that is involved in the regulation of neurotransmitter release.
In addition to its role in synaptic plasticity, LMTK3 has also been shown to play a role in the regulation of cellular processes that are involved in the development and maintenance of neural circuits. For example, LMTK3 has been shown to regulate the activity of genes that are involved in the development and maintenance of neuronal stem cells, which are cells that have the ability to develop into different types of neurons.
As a drug target or biomarker, LMTK3 is of interest because of its role in the regulation of synaptic plasticity and its involvement in the development and maintenance of neural circuits. Many neurological and psychiatric disorders are characterized by disruptions in synaptic plasticity, and LMTK3 may be a useful target for the development of new treatments for these disorders. Additionally, LMTK3 may also be a useful biomarker for tracking the effectiveness of current treatments for these disorders.
Protein Name: Lemur Tyrosine Kinase 3
Functions: Protein kinase which phosphorylates ESR1 (in vitro) and protects it against proteasomal degradation. May also regulate ESR1 levels indirectly via a PKC-AKT-FOXO3 pathway where it decreases the activity of PKC and the phosphorylation of AKT, thereby increasing binding of transcriptional activator FOXO3 to the ESR1 promoter and increasing ESR1 transcription (PubMed:21602804). Involved in endocytic trafficking of N-methyl-D-aspartate receptors (NMDAR) in neurons (By similarity)
The "LMTK3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMTK3 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165 | LOC100133177
